- ECOG PS (Eastern Cooperative Oncology Group Performance Status) is a clinical tool used to assess a cancer patient’s functional status—essentially, how the disease affects their daily living abilities.
- It ranges from 0 (fully active) to 5 (dead).
- It guides treatment decisions, eligibility for chemotherapy/clinical trials, prognosis, and dosing considerations.
ECOG Scale (0–5)
| ECOG PS | Description | Clinical Relevance (Pharmacy Perspective) |
|---|---|---|
| 0 | Fully active, no restrictions. | Eligible for aggressive chemotherapy, targeted therapy, immunotherapy, clinical trials. |
| 1 | Restricted in strenuous activity but ambulatory; can do light work. | Generally eligible for most standard regimens. Monitor tolerability. |
| 2 | Ambulatory >50% of waking hours, capable of self-care, unable to work. | Borderline: may need dose adjustments, less intensive regimens, or supportive care. |
| 3 | Limited self-care, confined to bed/chair >50% of waking hours. | Usually not candidates for aggressive therapy. Consider palliative/supportive measures or single-agent therapy. |
| 4 | Completely disabled, bed/chair bound. | Supportive/palliative care only. High risk for toxicity from systemic treatment. |
| 5 | Dead. | Not applicable. |
Why It Matters for Oncology Pharmacy
- Chemotherapy Eligibility
- Clinical Trial Enrollment
- Most trials require ECOG ≤ 1 or 2.
- Drug Toxicity Risk
- Higher ECOG → reduced organ reserve, higher toxicity, more ADRs.
- Pharmacist Role
- Evaluate fitness for systemic therapy.
- Recommend dose modifications.
- Ensure supportive care optimization (antiemetics, growth factors, pain management).
In summary: ECOG PS is a simple but powerful predictor of treatment tolerance and outcomes in oncology. As a pharmacist, you’ll constantly see ECOG PS referenced in chemotherapy protocols, guidelines (NCCN, ASCO), and clinical trials.
Links